Research Associate, Radiochemistry

About Ratio Therapeutics

ratiotx.com

Ratio Therapeutics is a discovery-to-early-clinical-stage biopharmaceutical company developing targeted radiopharmaceuticals for cancer patients. Its proprietary Trillium™ targeting scaffold combines pharmacokinetic modulation with advanced chelation to generate small-molecule targeting agents that selectively deliver therapeutic radioisotopes to tumors. The company advances candidates through preclinical and early clinical studies aiming to create best-in-class targeted radiotherapeutics with improved tumor targeting and safety. Ratio focuses on innovative chemistry and translational development to bring new radioligand therapies to patients.